Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation

Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has “driver gene mutations” and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, t he efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and t he directions of immunotherapy for patients with driver mutation.
 DOI: 10.3779/j.issn.1009-3419.2022.102.06
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research